Differences in chronic intragraft inflammation between positive crossmatch and ABO-incompatible kidney transplantation

Transplantation

Volumn 98, Issue 10, 2014, Pages 1089-1096

  Bentall, Andrew ^a,b   Herrera, Loren P ^a   Cornell, Lynn D ^a   Gonzales, Manuel A Moreno ^a   Dean, Patrick G ^a   Park, Walter D ^a   Gandhi, Manish J ^a   Winters, Jeffrey L ^a   Stegall, Mark D ^a  

^a MAYO CLINIC   (United States)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

ABO incompatible; Chronic histologic injury; HLA antibodies; Kidney transplant; Positive crossmatch

Indexed keywords

COMPLEMENT COMPONENT C4D; ALLOANTIBODY; BLOOD GROUP ABO SYSTEM;

ABO INCOMPATIBLE KIDNEY TRANSPLANTATION; ACUTE GRAFT REJECTION; ADULT; ANTIBODY TITER; ARTICLE; CHRONIC DISEASE; COMPARATIVE EFFECTIVENESS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CROSSMATCH KIDNEY TRANSPLANTATION; FEMALE; GLOMERULOPATHY; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEPLETION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; ADVERSE EFFECTS; AGED; BLOOD; BLOOD GROUP ABO SYSTEM; COMPARATIVE STUDY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFLAMMATION; INJURIES; KIDNEY; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TIME; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; INFLAMMATION; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927786975     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000188     Document Type: Article

References (30)

1. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008;86:681.
2. Genberg H, Kumlien G, Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008;85:1745.
3. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABOincompatible living kidney transplantation: a single-center experience. Transplantation 1998;65:224.
4. Futagawa Y, Terasaki PI. ABO incompatible kidney transplantationV an analysis of UNOS Registry data. Clin Transplant 2006;20:122.
5. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABOincompatible kidney transplantation in the United States. Transplantation 2012;93:603.
6. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006;6:1841.
7. Bach FH, Turman MA, Vercellotti GM, et al. Accommodation: a working paradigm for progressing toward clinical discordant xenografting. Transplant Proc 1991;23(1 pt 1):205.
8. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007;7:576.
9. Liptak P, Kemeny E, Morvay Z, et al. Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts. Am J Transplant 2005;5:2870.
10. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003;3:1017.
11. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013;13:76.
12. Loupy A, Hill GS, Nochy D, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2010;10:952; author reply 953.
13. Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant 2013;18:319.
14. Haidinger M, Schmaldienst S, Kormoczi G, et al. Vienna experience of ABO-incompatible living-donor kidney transplantation. Wien Klin Wochenschr 2009;121:247.
15. Tyden G. The European experience. Transplantation 2007;84(12 suppl):S2.
16. Hill GS, Nochy D, Bruneval P, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011;22:975.
17. Dean PG, Park WD, Cornell LD, et al. Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012;12:1551.
18. Park WD, Grande JP, Ninova D, et al. Accommodation in ABOincompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003;3:952.
19. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405.
20. Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997;3:196.
21. Lin Y, Soares MP, Sato K, et al. Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. J Immunol 1999;163:2850.
22. Stussi G, Huggel K, Lutz HU, et al. Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. Br J Haematol 2005;130:954.
23. Ishida H, Tanabe K, Ishizuka T, et al. Differences in humoral immunity between a non-rejection group and a rejection group after ABOincompatible renal transplantation. Transplantation 2006;81:665.
24. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004;78:221.
25. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010;10:582.
26. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008;8:2684.
27. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346.
28. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713.
29. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753.
30. Levey AS, Berg RL, Gassman JJ, et al. Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989;27:S73.